Golasept Tosse Grassa (Ambroxol Hydrochloride)

Golasept Tosse Grassa is indicated for conditions where mucus clearance is impaired.

• Acute cough associated with respiratory tract infections.
• Acute or chronic bronchitis with productive cough.
• Chronic obstructive pulmonary disease (COPD) presenting with sputum production.
• Post‑viral cough where mucus is thickened.
• Adjunct therapy after chest physiotherapy to enhance expectoration.

The safety profile of inhaled Ambroxol Hydrochloride reflects its mucolytic action and typical inhalation tolerability.

Common

• Mild throat irritation or dryness.
• Transient cough increase after inhalation.
• Unpleasant taste in the mouth.
• Slight headache.

Serious

• Allergic skin rash or urticaria.
• Severe bronchospasm or wheezing.
• Persistent nausea or vomiting.
• Swelling of the face, lips, or tongue.

Precautions should be observed before using Golasept Tosse Grassa to minimize risk and ensure appropriate use.

• Assess for known hypersensitivity to Ambroxol or any excipients.
• Use cautiously in patients with asthma or a history of bronchospasm.
• Evaluate renal or hepatic impairment before initiating therapy.
• Avoid use in uncontrolled respiratory infections without medical supervision.
• Pregnant or breastfeeding individuals should consult a healthcare professional.
• Do not exceed the recommended frequency of inhalations.

Ambroxol Hydrochloride may interact with other medications or substances, influencing its efficacy or safety.

Avoid

• Concurrent use of other mucolytic agents without medical advice.
• Combination with strong bronchodilators that may cause excessive airway irritation.
• Co‑administration with anticholinergic cough suppressants that could reduce mucus clearance.

Use with caution

• Concurrent inhaled corticosteroids; monitor for local irritation.
• Systemic antibiotics for respiratory infections; observe for additive gastrointestinal effects.
• Herbal preparations containing expectorants; adjust dosing as needed.